Clinical trial
A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
NCT05026866 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Study of Donanemab Versus Placebo in Participants at Risk for Cognitive and Functional Decline of Alzheimer's Disease
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Active, not recruiting
- Start date
- August 27, 2021
- Completion date
- November 30, 2027
- Enrollment
- 2,996 (estimated)
- Sites
- 216
Conditions
As the registry lists them; a condition with its own page is linked.